Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03691831 · ClinicalTrials.gov registry record · Phase 3
A Study of A-101 Topical Solution for the Treatment of Common Warts
A Phase 3 study, sponsored by Aclaris Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 502
- Enrollment target
NCT03691831: Completed Phase 3 study, sponsored by Aclaris Therapeutics.
NCT03691831 is a Phase 3 study that has completed, run by Aclaris Therapeutics. The registered enrollment target is 502 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (35% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03691831, a Phase 3 study, has completed, sponsored by Aclaris Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 502 participants
- Enrollment target
Study Summary
Phase 3 Study of A-101 Topical Solution in Subjects with Common Warts
Primary Outcome
The primary efficacy endpoint is the number of subjects whose identified common warts are determined to be clear on the Physician Wart Assessment (PWA) scale (PWA=0) at Visit 10 (Day 60). Efficacy will be assessed using the Physician's Wart Assessment Scale (PWA) which is a 4 point scale. A higher amount of warts cleared represents a better outcome.
Interventions
- OTHER Vehicle
- DRUG Active
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 502 participants |
| Start Date | 2018-09-13 |
| Est. Completion | 2019-07-09 |
| Phase | Phase 3 |
What the finished NCT03691831 record still lists
NCT03691831 is an interventional study that assigns participants to a tested intervention. The registered 502 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (35% lower).
The record links to 0 conditions, and to 2 interventions - of which Vehicle is the first listed.
NCT03691831 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03691831 about?
NCT03691831 is a clinical study titled "A Study of A-101 Topical Solution for the Treatment of Common Warts". Phase 3 Study of A-101 Topical Solution in Subjects with Common Warts
What is the current status of trial NCT03691831?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 502 participants. The study started on 2018-09-13. Estimated completion is 2019-07-09.
What interventions are being tested in trial NCT03691831?
The interventions under investigation include: Vehicle (OTHER), Active (DRUG).
Who is sponsoring clinical trial NCT03691831?
This trial is sponsored by Aclaris Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03691831's enrollment target sits among peer trials
502 743rd of 2000 higher than 1,258 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05646381 · 502 participants · Phase 2
A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis
- NCT05897632 · 502 participants · NA
CARE-CP (Testing a Cardiovascular Ambulatory Rapid Evaluation for Patients With Chest Pain)
- NCT05143931 · 503 participants · NA
Avoid and Resist Strategies for Weight Management
- NCT04442022 · 501 participants · Phase 2
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI